Clinical Study Protocol

HDClarity: a multi-site cerebrospinal fluid collection initiative to facilitate therapeutic development for Huntington’s disease

PROTOCOL NO.: UCL-CHDI-1

CHIEF INVESTIGATOR: Edward Wild, MA MB BChir PhD MRCP
UCL Institute of Neurology
Box 104
National Hospital for Neurology & Neurosurgery
Queen Square, London
WC1N 3BG, UK
Phone: + 44 207 611 0125
Fax: + 44 207 611 0129
e.wild@ucl.ac.uk

SPONSOR: University College London
Gower Street, London

FUNDING SOURCE: CHDI Foundation, Inc.
c/o CHDI Management, Inc.
155 Village Boulevard
Suite 200
Princeton, NJ 08540
Phone: + 1 609 945 9600
Fax: + 1 609 452 2160

PROTOCOL DATE AND VERSION: 21 June 2016 (Version No. 002)
PROTOCOL APPROVAL SIGNATURES

This Clinical Study Protocol is approved by:

Signature: [Signature] Date: 22 Jun 2016
Edward Wild, MA MB BChir PhD MRCP
Chief Investigator

Signature: [Signature] Date: 28 Jun 2016
Cristina Sampaio, MD, PhD
Chief Clinical Officer
CHDI Management, Inc.
## CHANGE LOG

<table>
<thead>
<tr>
<th>Date</th>
<th>Description of change(s)</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>2016-06-21</td>
<td>Addition of UK sites and update to CHDI study personnel</td>
<td>Elena Pak</td>
</tr>
</tbody>
</table>
Site Principal Investigator Signature Page

Protocol Number: UCL-CHDI-1

Protocol Title: HDClarity: a multi-site cerebrospinal fluid collection initiative to facilitate therapeutic development for Huntington’s disease


Funding Source: CHDI Foundation, Inc. (CHDI)
c/o CHDI Management, Inc.
155 Village Boulevard
Suite 200
Princeton, NJ 08540
Phone: +1 609 945 9600

By my signature below, I hereby attest that I have read and that I understand and will abide by all the conditions, instructions, and restrictions contained in the attached protocol.

I am aware of my responsibilities as an investigator under the guidelines for Good Clinical Practice (GCP), local regulations (as applicable), the Declaration of Helsinki, and the study protocol. I agree to conduct the study according to these guidelines and to appropriately direct and assist the staff under my control, who will be involved in the study.

Additionally, I will not initiate this study without approval of the appropriate Institutional Review Board (IRB)/Ethics Review Board (ERB). I understand that any changes in the protocol must be approved in writing by CHDI and the IRB/ERB before they can be implemented, except where necessary to eliminate hazards to participants.

<table>
<thead>
<tr>
<th>Site Principal Investigator’s Signature</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Site Principal Investigator Name (Print)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>
1. **Synopsis**

<table>
<thead>
<tr>
<th>Name of the Funding Source:</th>
<th>Protocol No.: UCL-CHDI-1</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHDI Foundation, Inc.</td>
<td></td>
</tr>
</tbody>
</table>

**Study Title:** HDClarity: a multi-site cerebrospinal fluid collection initiative to facilitate therapeutic development for Huntington’s disease

**Short Study Title:** HDClarity

**Planned Study Sites:** Multiple sites in Europe, North America and Australasia.

**Number of Participants planned:** Approximately 600 participants, across 6 clinical cohorts, will be enrolled at up to 30 sites.

**Chief Investigator:**
Dr. Edward Wild  
MRC Clinician Scientist, UCL Institute of Neurology;  
Honorary Consultant Neurologist, National Hospital for Neurology & Neurosurgery,  
Queen Square  
London WC1N 3BG, UK

**Study period:** 36 months  
Estimated date first subject enrolled: August 1, 2016  
Estimated date last subject completed: July 31, 2019

**Objectives:**

Primary: The primary objective of this study is to generate a high quality cerebrospinal fluid (CSF) sample collection for evaluation of biomarkers and pathways that will enable the development of novel treatments for Huntington’s disease (HD).

Secondary:

- To generate a high quality plasma sample collection matching the CSF collections, which will also be used to evaluate biomarkers and pathways of relevance to HD research and development.
- To collect phenotypic and clinical data for each participant.

**Study Design:**

This is an observational study. Participants will attend two study visits and may attend an optional third visit: a Screening Visit, a Sampling Visit and an optional Repeat Sampling Visit. During the Screening Visit, medical history, and clinical and phenotypic data will be obtained. Participants who meet the eligibility requirements of the study and are willing to continue in the study, will return for a Sampling Visit. During that visit, biosamples will be collected following an overnight fast: blood will be obtained via venipuncture and CSF will be obtained via lumbar puncture. Some participants may be invited to return for a Repeat Sampling Visit approximately 4-8 weeks later. Participant cohorts are as follows:
1. Healthy controls, n= 100
2. Early Pre-manifest HD, n=100
3. Late Pre-manifest HD, n=100
4. Early Manifest HD, n = 100
5. Moderate Manifest HD, n=100
6. Advanced Manifest HD, n=100

**Diagnosis and main criteria for inclusion:**
Healthy controls as well as Huntington’s disease gene expansion carriers (HDGECs) will be enrolled. The latter will include five groups: early pre-manifest, late pre-manifest HD, early HD, moderate HD and advanced HD.

**Inclusion Criteria:**

1. All eligible participants
   a. Are 21-75 years of age, inclusive; and
   b. Are capable of providing informed consent or have a legal representative authorized to give consent on behalf of the participant; and
   c. Are capable of complying with study procedures, including fasting, blood sampling and lumbar puncture; and
   d. Are participating in the Enroll-HD study; and
   e. Will have had an Enroll-HD visit within three months of the Sampling Visit.

2. For the **Healthy Control** group, subjects eligible are persons who meet the following criteria:
   a. Have no known family history of HD; or
   b. Have known family history of HD but have been tested for the huntingtin gene glutamine codon (CAG) expansion and are not at genetic risk for HD (CAG < 36).

3. For the **Early Pre-manifest HD** group, participants eligible are persons who meet the following criteria:
   a. Do not have clinical diagnostic motor features of HD, defined as Unified Huntington's Disease Rating Scale (UHDRS) Diagnostic Confidence Score < 4; and
   b. Have CAG expansion ≥ 40; and
   c. Have burden of pathology score, computed as (CAG – 35.5) x age, < 250.

4. For the **Late Pre-manifest HD** group, participants eligible are persons who meet the following criteria:
   a. Do not have clinical diagnostic motor features of HD, defined as Unified Huntington's Disease Rating Scale (UHDRS) Diagnostic Confidence Score < 4; and
   b. Have CAG expansion ≥ 40; and
   c. Have burden of pathology score, computed as (CAG – 35.5) x age, ≥ 250.

5. For **Early Manifest HD** group, participants eligible are persons who meet the following criteria:
   a. Have clinical diagnostic motor features of HD, defined as UHDRS Diagnostic Confidence Score = 4; and
   b. Have CAG expansion ≥ 36; and
   c. Have Stage I or Stage II HD, defined as UHDRS Total Functional Capacity (TFC) scores between 7 and 13 inclusive.
6. For **Moderate Manifest HD** group, participants eligible are persons who meet the following criteria:
   a. Have clinical diagnostic motor features of HD, defined as UHDRS Diagnostic Confidence Score = 4; and
   b. Have CAG expansion ≥ 36; and
c. Have Stage III HD, defined as UHDRS TFC scores between 4 and 6, inclusive.
7. For **Advanced Manifest HD** group, participants eligible are persons who meet the following criteria:
   a. Have clinical diagnostic motor features of HD, defined as UHDRS Diagnostic Confidence Score = 4; and
   b. Have CAG expansion ≥ 36; and
c. Have Stage IV HD, defined as UHDRS TFC scores between 0 and 3, inclusive.

**Exclusion Criteria:**
1. For all groups, participants are ineligible if they meet any of the following exclusion criteria:
   a. Current use of investigational drugs or participation in a clinical drug trial within 30 days prior to Sampling Visit; or
   b. Current intoxication, drug or alcohol abuse or dependence; or
c. If using any antidepressant, psychoactive, psychotropic or other medications or nutraceuticals used to treat HD, the use of inappropriate (e.g., non-therapeutically high) or unstable dose within 30 days prior to Sampling Visit; or
d. Significant medical, neurological or psychiatric co-morbidity likely, in the judgment of the Site Principal Investigator, to impair participant’s ability to complete study procedures; or
e. Needle phobia, frequent headache, significant lower spinal deformity or major surgery; or
   f. Antiplatelet or anticoagulant therapy within the 14 days prior to sampling visit, including but not limited to: aspirin, clopidogrel, dipyridamole, warfarin, dabigatran, rivaroxaban and apixaban; or
g. Clotting or bruising disorder; or
   h. Screening blood test results outside the lab’s normal range for the following: white cell count, neutrophil count, lymphocyte count, hemoglobin (Hb), platelets, prothrombin time (PT) and activated partial thromboplastin time (APTT); or
   i. Screening blood test results for C-reactive protein (CRP)>2× upper limit of normal; or
   j. Predictable non-compliance as assessed by Site Principal Investigator; or
   k. Inability or unwillingness to undertake any of the study procedures; or
   l. Exclusion during history or physical examination, final decision to be made by the Site Principal Investigator; including but not limited to:
      i. any reason to suspect abnormal bleeding tendency, e.g. easy bruising, petechial rash; or
      ii. any reason to suspect new focal neurological lesion, e.g. new headache, optic disc swelling, asymmetric focal long tract signs; or
      iii. any other reason that, in the clinical judgment of the operator or the Site Principal Investigator, it is felt that lumbar puncture is unsafe without brain imaging.
Sample Size:
The CSF and plasma samples collected in this study will be the basis of future biomarker analysis studies. Each of those studies will require a specific power calculation to determine how many samples to include in the analysis, but it is predicted, based on prior biomarker studies, that an n=50-75 per cohort will be sufficient for most studies. Since not all participants will be suitable for all biomarker studies, for example due to medication, we will aim to recruit 100 participants in each arm.

Only sites with access to in-patient facilities will likely be able to recruit volunteers with advanced HD, so those numbers will likely be smaller.

Finally, for the biomarkers discovered and analyzed, it may be important to understand the stability of the biomarker within participants over relatively short time periods. Thus, up to 20 participants per cohort will be invited to return for a Repeat Sampling Visit 4-8 weeks after their Sampling Visit.
Table of Contents

1. Synopsis ............................................................................................................. 5
2. List of Abbreviations and Definitions of Terms .............................................. 9
3. Roles & Responsibilities .................................................................................. 12
    3.1 Names, affiliations and roles of protocol contributors: ......................... 13
    3.2 Contact Information for the Study Sponsor ............................................. 13
    3.3 CHDI contact information ........................................................................ 14
    3.4 Medical Monitor contact information ..................................................... 14
4. Introduction ....................................................................................................... 15
    4.1 Background and Rationale ....................................................................... 15
    4.2 Rationale for Current Study ..................................................................... 15
        4.2.1 Ethical Considerations .................................................................... 16
5. Study Objectives ................................................................................................ 16
    5.1 Primary Objective ...................................................................................... 17
    5.2 Secondary Objective(s) ............................................................................ 17
6. Study Design ..................................................................................................... 17
    6.1 Overall Study Design ................................................................................ 17
7. Study Population ................................................................................................ 18
    7.1 Diagnosis and Main Selection Criteria ..................................................... 18
        7.1.1 Inclusion Criteria ............................................................................. 18
        7.1.2 Exclusion Criteria .......................................................................... 19
    7.2 Criteria for Termination of the Study ....................................................... 20
8. Study Procedures ............................................................................................... 21
    8.1 Description of Study Assessments ............................................................. 21
        8.1.1 Screening Visit ................................................................................ 22
        8.1.2 Sampling Visit ................................................................................. 23
        8.1.2.1 Participant Discharge ................................................................. 24
        8.1.3 Follow-up Telephone Call ............................................................... 24
        8.1.4 Optional Sampling Visit 2 ............................................................... 24
        8.1.4.1 Participant Discharge ................................................................. 25
        8.1.5 Follow-up Telephone Call 2 ........................................................... 25
9. Sample Collection Procedures ......................................................................... 25
9.1 Lumbar CSF Collection ................................................................. 25
9.2 Venous Blood Collection .............................................................. 26
10. Sample Processing Procedures ....................................................... 26
10.1 CSF Sample Processing ................................................................. 26
10.2 Serum Sample Processing .............................................................. 27
10.3 Plasma Sample Processing ............................................................. 27
11. Sample storage and shipment .......................................................... 27
12. Sample Quality Control ................................................................. 28
13. Analysis of CSF and plasma samples ............................................... 28
14. Medical Monitoring ................................................................. 28
15. Adverse Event Reporting and Documentation .................................. 29
15.1 Adverse Events ................................................................. 29
15.1.1 AE Severity Grading ............................................................ 29
15.1.2 AE Relationship to study procedures ........................................... 29
15.2 Serious Adverse Events ............................................................... 30
15.2.1 Serious Adverse Event Reporting .................................................. 30
15.3 Reporting incidents .................................................................... 30
15.4 Post-study Follow-up of Adverse Events ........................................ 31
16. Statistical Methodology ............................................................... 31
16.1 Determination of Sample Size ....................................................... 31
17. Study Management ................................................................. 32
17.1 Roles and responsibilities ............................................................. 32
17.2 Ethics and Regulatory Considerations ........................................... 32
17.2.1 Audits and Inspections ............................................................. 32
17.2.2 Ethics Committee Approval ....................................................... 32
17.3 Insurance .................................................................................... 32
17.4 Informed Consent Procedure ......................................................... 32
17.5 Data Collection, Retention and Monitoring .................................... 33
17.5.1 Data Entry/Electronic Data Capture System .................................. 33
17.5.2 Data Quality Control and Reporting ............................................ 33
17.5.3 Archival of Data ..................................................................... 33
17.5.4 Study Master Files ................................................................. 34
17.5.5 Source Documents ................................................................. 34
<table>
<thead>
<tr>
<th>Section</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>17.5.6</td>
<td>Monitoring</td>
<td>34</td>
</tr>
<tr>
<td>17.5.7</td>
<td>Data transfer</td>
<td>34</td>
</tr>
<tr>
<td>17.6</td>
<td>Biological samples (handling, processing and storage)</td>
<td>35</td>
</tr>
<tr>
<td>17.7</td>
<td>Amendments</td>
<td>35</td>
</tr>
<tr>
<td>17.8</td>
<td>Record Keeping</td>
<td>35</td>
</tr>
<tr>
<td>17.8.1</td>
<td>Health Insurance Portability Accountability Act of 1996</td>
<td>35</td>
</tr>
<tr>
<td>17.8.2</td>
<td>Retention of Study Documents</td>
<td>35</td>
</tr>
<tr>
<td>17.9</td>
<td>Reporting</td>
<td>35</td>
</tr>
<tr>
<td>18.</td>
<td>Appendix A – Site Principal Investigator Obligations</td>
<td>36</td>
</tr>
<tr>
<td>19.</td>
<td>References</td>
<td>38</td>
</tr>
</tbody>
</table>
### 2. List of Abbreviations and Definitions of Terms

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>AE</td>
<td>Adverse Event</td>
</tr>
<tr>
<td>APTT</td>
<td>Activated partial thromboplastin time</td>
</tr>
<tr>
<td>CAG</td>
<td>Cytosine-arginine-glutamine codon whose count in the HTT gene determines the genetic diagnosis of HD</td>
</tr>
<tr>
<td>CRP</td>
<td>C-reactive protein</td>
</tr>
<tr>
<td>CSF</td>
<td>Cerebrospinal fluid</td>
</tr>
<tr>
<td>eCRF</td>
<td>electronic Case Report Form</td>
</tr>
<tr>
<td>ERB</td>
<td>Ethics Review Board</td>
</tr>
<tr>
<td>GCP</td>
<td>Good Clinical Practice</td>
</tr>
<tr>
<td>Hb</td>
<td>Hemoglobin</td>
</tr>
<tr>
<td>HD</td>
<td>Huntington’s disease</td>
</tr>
<tr>
<td>HDGEC</td>
<td>Huntington’s disease gene expansion carrier</td>
</tr>
<tr>
<td>HTT</td>
<td>huntingtin protein</td>
</tr>
<tr>
<td>ICH Guidelines</td>
<td>International Conference on Harmonisation Guidance for Industry</td>
</tr>
<tr>
<td>IRB</td>
<td>Institutional Review Board</td>
</tr>
<tr>
<td>KMO</td>
<td>kynurenine mono-oxygenase</td>
</tr>
<tr>
<td>KP</td>
<td>kynurenine pathway</td>
</tr>
<tr>
<td>PT</td>
<td>Prothrombin time</td>
</tr>
<tr>
<td>SAE</td>
<td>Serious Adverse Event</td>
</tr>
<tr>
<td>TFC</td>
<td>Total Functional Capacity</td>
</tr>
<tr>
<td>TMS</td>
<td>Total Motor Score</td>
</tr>
<tr>
<td>UHDRS</td>
<td>Unified Huntington's Disease Rating Scale</td>
</tr>
</tbody>
</table>
3. Roles & Responsibilities

3.1 Names, affiliations and roles of protocol contributors:

Beth Borowsky, PhD; CHDI Management; Funding Source Science Director

Cheryl Fitz-Attas, PhD, MBA; CHDI Management; Funding Source Vice President Clinical Research

Bernhard Landwehrmeyer, MD PhD; CHDI Management and Ulm University Hospital; Funding Source Medical Consultant

Blair Leavitt, MD; The University of British Columbia, Centre for Molecular Medicine and Therapeutics; Site Principal Investigator

Jan Lewerenz, MD; Ulm University Hospital; Site Principal Investigator

Cristina Sampaio, MD PhD; CHDI Management; Funding Source Chief Clinical Officer

Edward Wild, MD; University College London, Institute of Neurology; Chief Investigator

3.2 Contact Information for the Study Sponsor

Suzanne Emerton, Research Portfolio Coordinator
Joint Research Office
1st Floor Maple House (Suite B)
149 Tottenham Court Road
London W1T 7DN

Postal Address: Joint Research Office,
UCL, Gower Street, London WC1E 6BT

Phone: +44 203 447 7430
Fax: +44 203 108 2312
Email: Suzanne.Emerton@uclh.nhs.uk
Website www.ucl.ac.uk/jro
3.3 CHDI contact information

MEDICAL CONTACT
Cristina Sampaio, MD, PhD, Chief Clinical Officer
CHDI Management, Inc.
155 Village Boulevard, Suite 200
Princeton, NJ 08540, USA
Phone: +1 609 945 9639
Fax: +1 609 452 2160
E-mail:Cristina.Sampaio@chdifoundation.org

PROJECT MANAGER and CHDI PRIMARY CONTACT
Elena Pak
CHDI Management, Inc.
350 Seventh Avenue, Suite 200
New York, NY 10001, USA
Phone: +1 212 660 8111
Fax: +1 212 239 2101
E-mail:elena.pak@chdifoundation.org

3.4 Medical Monitor contact information
Tiago Mestre, MD
Phone: +1 617 302 5513
4. Introduction

4.1 Background and Rationale

Huntington’s disease (HD) is an autosomal dominant genetic disease, which typically manifests beginning in adulthood in the form of movement symptoms, cognitive decline, and psychiatric changes (Roos, 2010). Currently the only approved treatment for HD is tetrabenazine, but several clinical trials are expected to launch in the next few years to explore novel therapeutic approaches to treating this disease. In preparation for such trials, biomarkers are needed to evaluate: (1) how well these novel therapeutics reach their intended target and have a biological effect (pharmacodynamic markers); (2) the effectiveness of these novel therapeutics at improving clinical signs and symptoms (efficacy biomarkers); and (3) the state of disease patients are in throughout the trial (disease progression biomarkers). Cerebrospinal fluid (CSF) is an ideal fluid compartment for assessing HD biomarkers, particularly pharmacodynamics markers, due to its proximity to the brain.

Evidence from preclinical animal studies as well as post-mortem human brain studies suggests that the kynurenine pathway (KP) may be abnormally regulated in HD (Guidetti et al., 2004). Thus, this enzymatic pathway may be a target for therapeutic intervention. However, the KP has not been extensively investigated in HD patients and premanifest HD gene expansion carriers (HDGECs). To further investigate the potential dysregulation of the pathway, and inter-participant variability of the dysregulation, we propose to measure levels of some of the key KP metabolites in CSF and plasma from HD patients, premanifest HDGECs and healthy controls. The results of this study will serve not only to support the biological rationale for pursuing this line of treatment for HD, but will also set the ground work for the use of particular metabolites as pharmacodynamic biomarkers in future clinical trials of therapeutics modulating the KP, such as inhibitors of kynurenine mono-oxygenase (KMO).

Several therapeutic approaches focused on lowering huntingtin protein (HTT) in the brain are currently pursued, and studies in animals suggest this is a promising approach (Kordasiewicz, 2012). However, one of the key tools needed to pursue such approaches in humans is the ability to demonstrate that the intervention did lower HTT levels in the brain. Fortunately, assays are being developed that can detect HTT in CSF. We propose to further the development and validation of CSF HTT assays by measuring HTT levels in CSF and plasma from HD patients, premanifest HDGECs and healthy controls. The results of these studies will lead to the establishment of the best practices for measuring HTT in CSF from patients before and after HTT lowering therapies.

Several CSF and plasma HD biomarker discovery programs have resulted in the generation of a “hot list” of proteins potentially differentially expressed in HD. While promising, this list needs to be replicated in a new sample set, potentially with more quantitative assays. We propose to use samples collected in the current study to further explore the potential of these and other proposed biomarkers to become validated HD CSF and plasma biomarkers.

4.2 Rationale for Current Study

With promising new therapeutic trials expected to begin in the next few years, exploration of potential biomarkers needs to be accelerated now. There is currently no high quality repository of CSF from well-characterized HDGECs spanning the disease spectrum. The
current study will provide such a repository in order to expedite the research into biomarkers for HD.

4.2.1 Ethical Considerations

Institutional review board and ethics review board
Sites will be responsible for obtaining all appropriate approvals, supported by a CHDI-approved informed consent form. ERB and/or IRB approval will be sought for each site in each country as per their regulations prior to the start of the study activities at that site. In particular, as relates to any UK participants or UK National Health Service (NHS) site, no study activities involving such UK participants or any such NHS site will occur until an application covering all proposed activities at any such NHS site or involving such UK participants, submitted via the Integrated Research Application System (IRAS), has been approved from an NHS Research Ethics Committee (REC).

Informed consent procedure
All participants must give informed consent prior to undertaking study procedures and these informed consents must be obtained by clinical site staff using approved processes. Signed consent forms will be maintained in a secure designated location at the site.

Subject safety
The procedures for performing lumbar punctures and venous blood draws have been designed to maximize participant safety.

Subject risk
Study-related risks are explained in the informed consent document. In particular, the following risks may be associated with lumbar puncture: pain; headache (approximately 5%), infection, bleeding and nerve root damage. Most headaches resolve spontaneously but occasionally a headache may be persistent; in rare cases this may necessitate treatment, which may include a second procedure (a blood patch), carried out in a clinical setting.

See Appendix A – Site Principal Investigator Obligations for additional information.

5. Study Objectives

The overall objective of this study is to generate a high quality CSF sample collection that can be used to identify and validate biomarkers for HD clinical development. In one usage, the sample collection will be assayed to determine if the KP is dysregulated in premanifest and early HD in comparison to healthy controls, and to evaluate the variability in KP metabolite levels within each participant group. This information will help assess the potential for KMO inhibitors as therapies for HD and guide the use of such assays as pharmacodynamic biomarkers in clinical trials. The sample collection will also enable the further development and validation of assays to measure HTT in CSF, which may be an attractive pharmacodynamic biomarker for HTT lowering clinical trials. Last, the sample collection will enable us to continue evaluation of a number of potential novel biomarkers of disease progression and, potentially, efficacy in HD.

CSF and blood samples will be collected from select sites throughout the world using a standardized protocol. Careful collection of clinical and phenotypic data on each donor will enable us to appropriately select subsets of samples for each set of experimental assays.
5.1 Primary Objective
The primary objective of this study is to generate a high quality CSF sample collection for evaluation of biomarkers and pathways that will enable the development of novel treatments for HD.

5.2 Secondary Objective(s)
The secondary objectives of this study are:
- To generate a high quality plasma sample collection matching the CSF collections, which will also be used to evaluate biomarkers and pathways of relevance to HD research and development.
- To collect phenotypic and clinical data for each participant.

6. Study Design
6.1 Overall Study Design
This is a Phase 0 observational study.

Recruitment: Participants will be recruited at up to 30 sites in Europe, North America and Australasia from among participants in the Enroll-HD study who will have had an Enroll-HD study visit within three months of the Sampling Visit.

Study Visits: Participants will attend two study visits: a Screening Visit and a Sampling Visit. During the Screening Visit, which may coincide with an Enroll-HD visit, medical history, clinical and phenotypic data (including a screening blood sample) will be obtained. These data will determine participant eligibility for participation in the study and will be used in the analysis of biomarker data. Participants meeting the eligibility requirements of the study and willing to continue in the study, will return for a Sampling Visit within 30 days of the Screening Visit. During that visit, biosamples will be collected following an overnight fast: blood will be obtained via venepuncture and CSF will be obtained via lumbar puncture. Participants will be contacted by telephone approximately 24-72 hours after the Sampling Visit. Some participants may be invited to return for an optional Repeat Sampling Visit 4-8 weeks following the Sampling visit.

Enroll-HD visits will provide the clinical data for this study. Where possible, routine, planned Enroll-HD visits will be used to plan recruitment into HDCALLITY. However, where such scheduling may jeopardise a potential participant’s inclusion in HDCALLITY, assessments equivalent to an Enroll-HD Core visit may be performed at the screening visit, after prior approval by the Chief Investigator.
Biosample Preparation: Samples will be processed and stored as described in Sections 10.1, 10.2 and 10.3 until ready for analysis.

Laboratory analyses: Samples will be shipped to laboratories, as directed by CHDI, for multiple HD research investigations including, but not limited to, the evaluation of the KP, measurement of HTT and other biomarker discovery or validation studies.

Statistical analysis: For each set of laboratory analyses conducted, a statistical analysis plan will be finalized before samples are sent to the laboratory conducting the studies.

7. Study Population
Six participant cohorts will be included in the study:

1. Healthy controls, n= 100
2. Early Pre-manifest HD, n=100
3. Late Pre-manifest HD, n=100
4. Early Manifest HD, n = 100
5. Moderate Manifest HD, n=100
6. Advanced Manifest HD, n=100

7.1 Diagnosis and Main Selection Criteria
A total of 600 male and female participants, aged between 21 and 75 years, inclusive, will be enrolled in the study. Eligible participants include healthy controls, people who are in the early pre-manifest and late pre-manifest stage of HD, and people diagnosed with early HD, moderate HD or advanced HD.

7.1.1 Inclusion Criteria
1. All eligible participants:
   a. Are 21-75 years of age, inclusive; and
   b. Are capable of providing informed consent or have a legal representative authorized to give consent on behalf of the participant; and
   c. Are capable of complying with study procedures, including fasting, blood sampling and lumbar puncture; and
   d. Are participating in the Enroll-HD study; and
   e. Will have had an Enroll-HD visit within three months of the Sampling Visit.

2. For the Healthy Control group, subjects eligible are persons who meet the following criteria:
   a. Have no known family history of HD; or
   b. Have known family history of HD but have been tested for the huntingtin gene glutamine codon (CAG) expansion and are not at genetic risk for HD (CAG < 36).

3. For the Early Pre-manifest HD group, participants eligible are persons who meet the following criteria:
   a. Do not have clinical diagnostic motor features of HD, defined as Unified Huntington's Disease Rating Scale (UHDRS) Diagnostic Confidence Score < 4; and
   b. Have CAG expansion ≥ 40; and
   c. Have burden of pathology score, computed as (CAG – 35.5) × age, < 250.

4. For the Late Pre-manifest HD group, participants eligible are persons who meet the following criteria:
a. Do not have clinical diagnostic motor features of HD, defined as Unified Huntington's Disease Rating Scale (UHDRS) Diagnostic Confidence Score < 4; and
b. Have CAG expansion ≥ 40; and
c. Have burden of pathology score, computed as (CAG – 35.5) x age, ≥ 250.

5. For Early Manifest HD group, participants eligible are persons who meet the following criteria:
   a. Have clinical diagnostic motor features of HD, defined as UHDRS Diagnostic Confidence Score = 4; and
   b. Have CAG expansion ≥ 36; and
   c. Have Stage I or Stage II HD, defined as UHDRS Total Functional Capacity (TFC) scores between 7 and 13 inclusive.

6. For Moderate Manifest HD group, participants eligible are persons who meet the following criteria:
   a. Have clinical diagnostic motor features of HD, defined as UHDRS Diagnostic Confidence Score = 4; and
   b. Have CAG expansion ≥ 36; and
   c. Have Stage III HD, defined as UHDRS TFC scores between 4 and 6, inclusive.

7. For Advanced Manifest HD group, participants eligible are persons who meet the following criteria:
   a. Have clinical diagnostic motor features of HD, defined as UHDRS Diagnostic Confidence Score = 4; and
   b. Have CAG expansion ≥ 36; and
   c. Have Stage IV HD, defined as UHDRS TFC scores between 0 and 3, inclusive.

7.1.2 Exclusion Criteria

1. For all groups, participants are ineligible if they meet any of the following exclusion criteria:
   a. Use of investigational drugs or participation in a clinical drug trial within 30 days prior to Sampling Visit; or
   b. Current intoxication, drug or alcohol abuse or dependence; or
   c. If using any antidepressant, psychoactive, psychotropic or other medications or nutraceuticals used to treat HD, the use of inappropriate (e.g., non-therapeutically high) or unstable dose within 30 days prior to the Sampling Visit; or
   d. Significant medical, neurological or psychiatric co-morbidity likely, in the judgment of the Site Principal Investigator, to impair participant’s ability to complete study procedures; or
   e. Needle phobia, frequent headache, significant lower spinal deformity or major surgery; or
   f. Antiplatelet or anticoagulant therapy within 14 days prior to Sampling Visit, including but not limited to: aspirin, clopidogrel, dipyridamole, warfarin, dabigatran, rivaroxaban and apixaban; or
   g. Clotting or bruising disorder; or
h. Screening blood test results outside the lab’s normal range for the following: white cell count, neutrophil count, lymphocyte count, hemoglobin (Hb), platelets, Prothrombin time (PT) and activated partial thromboplastin time (APTT); or

i. Screening blood test results for C-reactive protein (CRP) >2× upper limit of normal; or

j. Predictable non-compliance as assessed by the Site Principal Investigator; or

k. Inability or unwillingness to undertake any of the study procedures; or

l. Exclusion during history or physical examination, final decision to be made by the Site Principal Investigator; including but not limited to:

   i. any reason to suspect abnormal bleeding tendency, e.g. easy bruising, petechial rash; or

   ii. any reason to suspect new focal neurological lesion, e.g. new headache, optic disc swelling, asymmetric focal long tract signs; or

   iii. any other reason that, in the clinical judgment of the operator or the Site Principal Investigator, it is felt that lumbar puncture is unsafe without brain imaging.

7.2 Criteria for Termination of the Study

The Chief Investigator may terminate this study prematurely as follows: (a) on an immediate basis for any reason reasonably related to the health or safety of the participants and (b) upon 90 days written notice to CHDI for any other reason. CHDI may terminate this study prematurely for any reason. The Sponsor and Institutional Review Board(s) (IRBs)/Ethics Review Board(s) (ERBs) must be informed promptly.

If the study is prematurely terminated or suspended for any reason, the Site Principal Investigator/institution should promptly inform the study participants and should assure appropriate follow-up for them.
### 8. Study Procedures

<table>
<thead>
<tr>
<th>Visit Number</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Visit Type</strong></td>
<td>Screening</td>
<td>Sampling</td>
<td>Telephone Follow-Up</td>
<td>Optional Repeat Sampling³</td>
<td>Telephone Follow-Up³</td>
</tr>
<tr>
<td><strong>Days</strong></td>
<td>-30 to -1</td>
<td>Day 0</td>
<td>Day 1 to 3</td>
<td>Day 28 - 56</td>
<td>*1-3 Days After Optional Sampling Visit</td>
</tr>
<tr>
<td><strong>Study Procedure</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Informed Consent</td>
<td>X</td>
<td>X¹</td>
<td></td>
<td>X¹</td>
<td></td>
</tr>
<tr>
<td>Inclusion/Exclusion Criteria review</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Demographics update</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Confirm Enroll-HD core assessments completed within last two months; if not, check CI permission in place and complete Enroll-HD core assessments (listed at section 8.1.1)</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brief Physical Exam</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medical History update</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prior/Concomitant Medication update</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Standard Neurological Examination</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total Motor Score (TMS)</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vital Signs (BP, pulse, body temp)</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Safety Laboratory Assessments</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adverse Events</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Final Eligibility Check</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lumbar CSF Collection</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Venous Blood Draw²</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CSF and Blood Sample Processing</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CSF QC Processing</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

¹Confirm and record continued consent.
²Obtain venous blood sample immediately after CSF collection is complete.
³For selected subjects only
8.1 Description of Study Assessments
Participants will attend two study visits and may attend an optional third visit: a Screening Visit, a Sampling Visit and an optional Repeat Sampling Visit. The Screening and Sampling Visits should be no more than 30 days apart. The screening visit may occur with an Enroll-HD visit. The optional Repeat Sampling Visit will occur within 4-8 weeks of the first sampling visit.

Information regarding occurrence of adverse events (AEs) will be captured throughout the study. Duration (start and stop dates and times), severity/grade, outcome, treatment and relation to study procedures will be recorded on the electronic case report form (eCRF).

8.1.1 Screening Visit

- The study will be described in detail to prospective participants and informed consent obtained.
- Confirm that Enroll-HD study core assessments have been performed within the last two months. If not, confirm that approval is in place from the CI and perform the Enroll-HD core assessments during the Screening Visit according to the procedures in the Enroll-HD Protocol and study materials. The Enroll core assessments currently include:
  - Height and weight measurement
  - UHDRS motor assessment, diagnostic confidence score, total functional capacity and Independence Scale.
  - Short Problem behaviours assessment (PBA-S)
  - Symbol-digit modality test
  - Stroop word reading
  - Stroop color naming
  - Categorical verbal fluency
- Medical history update since the last Enroll-HD study visit, including medication history and co-morbidities, is obtained.
- Demographic information update since the last Enroll-HD study visit.
- A standard neurological examination is performed as below, as well as a brief general physical examination. Evidence of possible bleeding tendency such as bruises or petechial rash should be noted.
  - Cranial nerves
    - visual acuity
    - visual fields to confrontation
    - fundoscopy (including appearance of discs and presence / absence of venous pulsations)
    - smooth pursuit and saccadic eye movements
    - facial sensation
    - jaw power
- facial symmetry and power
- bedside auditory acuity
- palatal elevation
- pharyngeal sensation
- cough
- Sternocleidomastoid muscle and trapezius power
  - Upper and lower limbs
    - Tone
    - Proximal and distal power
    - Reflexes (-, +/-, +, ++, +++)
    - Pinprick sensation
    - Plantar responses
    - Coordination

- Up to 15 ml of venous blood is drawn according to local clinical standards and procedures, and routine blood tests performed by a local accredited clinical laboratory:
  - Full blood count
  - Clotting profiles: PT and APTT
  - CRP

If the blood count or clotting profiles are outside normal range, or if CRP is greater than 2× the upper limits of normal the subject will not be booked for a sampling visit. The Site Principal Investigator will act on any abnormalities according to clinical judgment.

If participants do not fulfill all inclusion criteria, they may be rescheduled to repeat some or all of the screening assessments above with the prior approval of the Chief Investigator.

If these assessments confirm all the eligibility requirements are met for the study, a date will be given via a telephone call for the sampling visit.

### 8.1.2 Sampling Visit

- The sampling visit is scheduled in such a way to allow for the lumbar puncture to be performed between 8:00 and 10:30 am local time. All participants will be asked to fast from midnight the night before their appointment, but are permitted to drink water freely. Compliance with instructions to fast is recorded.

- If participant has not complied with pre-sampling instructions such as fasting or medications, or if the site investigator deems the sampling procedure unsafe, unwise or unlikely to produce satisfactory samples, the participant should be sent home, and the sampling rescheduled at the discretion of the site investigator.

- Participant continued consent to participate is confirmed and recorded.

- The results of the routine laboratory examination are reviewed and recorded.

- Medical and concomitant medication history is updated.

- Measurement of vital signs.
The check-list ‘Inclusion and Exclusion Criteria – Sampling Visit’ is completed. Any changes to medical history and medication are noted.

The neurological examination and brief physical exam are repeated for safety.

The Total Motor Score (TMS) of the UHDRS is performed.

Lumbar CSF Collection is performed. (See Section 9.1 for complete instructions)

Venous blood sampling is performed immediately after CSF collection is complete. (See Section 9.2 for complete instructions)

Process CSF, Serum and Plasma samples per Sections 10.1, 10.2 and 10.3, respectively

Perform sample quality control (QC) per Section 12.

Store samples per Section 11.

8.1.2.1 Participant Discharge

Participants are observed for potential complications as per routine clinical practice and discharged once appropriate. Record any AEs.

Participant is discharged by nurses with instructions for over the counter pain medication and hydration in the event of headache.

8.1.3 Follow-up Telephone Call

Contact participant 24 to 72 hours following Sampling Visit to collect any AE and/or concomitant medication data.

8.1.4 Optional Sampling Visit 2

This visit is optional. Participant continued consent to participate is confirmed and recorded.

This visit should be scheduled 4 - 8 weeks following the initial Sampling Visit.

The sampling visit is scheduled in such a way to allow for the lumbar puncture to be performed between 8:00 and 10:30 am local time. Participants performing this optional visit will be asked to fast from midnight the night before their appointment, but are permitted to drink water freely. Compliance with instructions to fast is recorded. If the participant did not fast, they will be sent home, and the procedure rescheduled.

The results of the routine laboratory examination are reviewed and recorded.

The check-list ‘Inclusion and Exclusion Criteria – Sampling Visit’ is filled out. Any changes to medical history and medication are noted.

The neurological examination and brief physical exam are repeated for safety. The TMS of the UHDRS is repeated.

Lumbar CSF Collection is performed. (See Section 9.1 for complete instructions)

Venous blood sampling is performed immediately after CSF collection is complete. (See Section 9.2 for complete instructions)
- Process CSF, Serum and Plasma samples per Sections 10.1, 10.2 and 10.3, respectively
- Measurement of vital signs
- AE recording
- Perform sample QC per Section 12.
- Store samples per Section 11.

8.1.4.1 Participant Discharge

Participants are observed for potential complications as per routine clinical practice and discharged once appropriate. Record any AEs.

Participant is discharged by nurses with instructions for over the counter pain medication and hydration in the event of headache.

8.1.5 Follow-up Telephone Call 2

Contact participant 24 to 72 hours following optional Sampling Visit to collect any AE and/or concomitant medication data.

9. Sample Collection Procedures

9.1 Lumbar CSF Collection

1. Ensure that all equipment is on hand and that ice is available for CSF collection and transportation of samples to the lab.
2. Ensure availability and settings of centrifuges for appropriate temperatures and timely processing of CSF and blood samples.
3. Pre-cool CSF collection tubes on ice.
4. Prepare a sterile field containing all equipment needed, label tubes.
5. Place participant into lateral decubitus position with pillow between knees.
6. Identify L4/5 or L3/4 space using surface markings.
7. Disinfect skin using pre-filled sponge.
8. It is highly recommended that adequate lidocaine is used to reduce the discomfort of this lumbar puncture procedure. If, after noting allergies or sensitivities to lidocaine and discussing the risks and benefits of local anaesthesia, it is decided to forgo this step, it should be noted in the electronic case report form (eCRF). Inject up to 5ml of 2% lidocaine for local anaesthesia. Use the 25g needle and inject lidocaine to raise a skin wheal. Then inject lidocaine more deeply.
9. Obtain CSF using the supplied spinal needle. If the participant is thin, do not insert the deep infiltration needle all the way. Use only about 2/3 of its length (to prevent entering the subarachnoid space with anything other than the pencil-point spinal needle).
10. If CSF cannot be obtained, up to three needles may be used. An alternative design of spinal needle supplied by the site may be used if, after at least one attempt with the supplied needle, it is felt this will increase the chance of success.
11. An adjacent space may be used (with further lidocaine, max. total 10 ml, if needed).
12. If necessary, CSF space may be located by sitting patient up, but once CSF is seen, it is recommended to have patient lie back in lateral decubitus position for 30 seconds before collection begins. Document positions of patient during puncture and collection in the eCRF.

13. Document the space used for lumbar puncture, the number of attempts and volume of lidocaine used in the eCRF.

14. Omit pressure measurement for all participants (because spinal manometers are not polypropylene).

15. CSF is collected in 50ml tubes placed on ice in the Styrofoam cup.

16. Collect the first 1 ml of CSF into the supplied tube labelled ‘CSF’. If the first 1 ml (approx. 15 drops) is not macroscopically bloody, continue sampling CSF in the same tube up to 15-20 ml, as allowed locally, keeping the tube in the ice cup. If the first 1 ml is macroscopically bloody, stop collecting CSF by reinserting the stylet partially, discard the tube, and collect a second 1 ml in a new pre-cooled ‘CSF’ tube, and examine it visually for blood contamination. If it is free of blood, continue collecting CSF up to 14-19 ml. If the second separately collected ml of CSF is also macroscopically bloody, discard the tube, and continue to collect 13-18 ml of CSF in a third pre-cooled ‘CSF’ tube. Stop collecting CSF when sampling time exceeds 20 minutes. Document these details in the eCRF.

17. Place cap on tube and leave on crushed ice until further processing.

18. Reinsert the stylet before withdrawing the needle.

19. Cover the puncture site with sterile dressing.

20. Record time of CSF collection.

21. At the discretion of the Site Principal Investigator, participants may be instructed to lie flat for one hour.

22. Transport samples immediately to laboratory for processing.

9.2 Venous Blood Collection

Venous blood is drawn immediately after CSF collection is complete, recording the time. The following samples are acquired:

- 1 x 8.5 ml serum tube.
- 4 x 10 ml blood in lithium heparin tubes. Gently invert each tube 10 times immediately after collection, and place on ice.
- If venepuncture with vacuum tubes proves challenging, a needle and syringe may be used and the blood transferred immediately into the vacuum tubes, observing safety precautions.

10. Sample Processing Procedures

10.1 CSF Sample Processing

1. Register tube bar-codes as instructed.

2. All CSF processing should be done on ice, beginning within 15 minutes of completion of collection.
3. Agitate the entire CSF sample for 10 seconds to homogenise CSF.

4. Use 200 µl of the CSF to determine white blood cell count and erythrocyte count per µl according to local GLP-approved laboratory practice. This should be done in triplicate within 60 minutes of collection and all values recorded in the CRF.

5. Centrifuge the 50 ml tube containing residual CSF at 400 x g for 10 min at 4°C to remove cells while preserving cell integrity for potential future use.

6. Transfer supernatant into a single tube labelled “CSF supernatant” and agitate for 10 seconds to homogenise CSF.

7. Aliquot the CSF into 300 µl aliquots, using supplied pipette tips and cryovials labelled “CSF”.

8. Gently resuspend pellet in 300µL of supplied preservative solution and transfer to the cryovial labelled “Cells from CSF”.

9. Freeze CSF aliquots and resuspended cells on dry ice and store at -80°C.

10. Record time of freezing

10.2 Serum Sample Processing

1. Spin serum tube at 2000 x g at room temperature for 10 min immediately upon arrival in the onsite processing laboratory.

2. Transfer 1500 µl of the supernatant into each of 2 separate 2 ml cryovials labeled “serum”, freeze on dry ice and store in -80°C.

3. Record time of freezing

10.3 Plasma Sample Processing

1. Spin lithium heparin tubes at 1300 x g for 10 min at 4°C immediately on arrival.

2. Discard any tubes whose plasma is pink due to hemolysis.

3. Combine the supernatant in one tube labelled “plasma” and mix by inverting 10 times. Store on crushed ice.

4. Divide lithium heparin plasma into 300 µl aliquots using supplied pipette tips and cryovials labeled ‘plasma’.

5. Freeze samples on dry ice and store at -80°C.

6. Record time of freezing.

11. Sample storage and shipment

- Store samples in a -80°C freezer.
- Log samples in eCRF.
- Ship samples to BioRep within 2 months, or as instructed by CHDI. Shipping must only be done on Mondays. The package should contain sufficient dry ice for three days.
12. **Sample Quality Control**

The following quality control measures will be carried out to identify and flag samples subject to potential confounders:

- Microscopic erythrocyte count in CSF is performed locally in triplicate and recorded on eCRF. Cut-off for flagging: > 1000 erys/µl.
- Microscopic leukocyte count in CSF is performed locally in triplicate and recorded on eCRF. Cut-off for flagging: ≥ 5 cells/µl.
- Hb, albumin and quantitative immunoglobulins levels will be measured in acellular CSF by a central lab.
- Albumin and quantitative immunoglobulin levels will be measured in serum by a central lab.

The results of the QC and the flagging of samples will be recorded on the eCRF and communicated to the respective analysts as well as to the biorepository for flagging in a mutually agreed format. If Hb levels in CSF are elevated, additional measurements may be made from the CSF cell pellet.

13. **Analysis of CSF and plasma samples**

CSF and plasma samples will be shipped to sample analysts (e.g., Tandem Labs, Inc., A LabCorp Company, San Diego, CA) for measurement of KP metabolite levels according to previously established and analytically validated methodologies. Specifically, the levels of the following KP metabolites will be measured in CSF and plasma: kynurenine, kynurenic acid, 3-OH-kynurenine, quinolinic acid and anthranilic acid. In addition, the plasma levels of tryptophan will be determined, which will allow for an additional control for lack of compliance with the stipulation of an overnight fast.

Additional measurements, including but not limited to other KP metabolites or precursors, the levels of soluble HTT, and other putative biomarkers may also be measured at appropriate laboratories, to be determined.

The primary outcome measurements are of unknown clinical significance. The detailed analysis may include measurements of potential clinical significance in relation to conditions other than HD, such as oligoclonal bands. However, patients with other neurological diagnoses or unexpected examination findings will be excluded. Therefore any abnormal results, obtained on a linked-anonymised basis, will remain of indeterminate clinical significance and will not be fed back to the participant or sites.

A full statistical analysis plan will be prepared under the supervision of CHDI by statisticians and the respective analytical laboratories prior to shipping samples to the sample analysts.

14. **Medical Monitoring**

The Medical Monitor should be contacted directly at this number to report medical concerns or questions regarding safety:

   Tiago Mestre, M.D.
   + 1 647 302 5513
15. **Adverse Event Reporting and Documentation**

15.1 **Adverse Events**

An adverse event (AE) is any untoward medical occurrence during a clinical investigation and that does not necessarily have a causal relationship with study treatments or procedures. An AE is therefore any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the administration of study procedures.

The Site Principal Investigator will probe, via discussion with the participant, for the occurrence of AEs during each participant visit, after the screening visit, and record the information in the site’s source documents. AEs will be recorded in the patient eCRF. AEs will be described by duration (start and stop dates and times), severity, outcome, treatment and relation to study procedures if applicable, or if unrelated, the cause.

15.1.1 **AE Severity Grading**

The severity of an AE will be graded on a 5-point scale (Common Terminology Criteria for Adverse Events v3.0 (CTCAE; http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm) defined as follows:

<table>
<thead>
<tr>
<th>Grade</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Mild AE</td>
</tr>
<tr>
<td>2</td>
<td>Moderate AE</td>
</tr>
<tr>
<td>3</td>
<td>Severe AE</td>
</tr>
<tr>
<td>4</td>
<td>Life-threatening or disabling AE</td>
</tr>
<tr>
<td>5</td>
<td>Death related to AE</td>
</tr>
</tbody>
</table>

15.1.2 **AE Relationship to study procedures**

The relationship of an AE to the study procedures will be evaluated according to the following guidelines:

**Probable:** This category applies to AEs which are considered with a high degree of certainty to be related to the study procedure. An AE may be considered probably related to the study procedure if:

1. It follows a reasonable temporal sequence from administration of the study procedure;
2. It cannot be reasonably explained by the known characteristics of the participant’s clinical state, or by environmental or toxic factors;
3. It follows a known pattern of response to the study procedure;

**Possible:** This category applies to those AEs in which the connection with the study procedure appears unlikely but cannot be ruled out with certainty. An AE may be considered as possibly related if it has at least two of the following:

1. It follows a reasonable temporal sequence from the study procedure
2. It may readily have been produced by the participant’s clinical state, or by environmental or toxic factors;
3. It follows a known response pattern to the study procedure.
Unrelated: This category applies to those AEs which are judged to be clearly and incontrovertibly due to extraneous causes (disease, environment, etc.) and do not meet the criteria for study procedure relationship listed under possible or probable.

15.2 Serious Adverse Events

A Serious Adverse Event (SAE) is defined as any AE that results in any of the following outcomes:

- death
- a life-threatening adverse experience
- inpatient hospitalization or prolongation of existing hospitalization
- a persistent or significant disability/incapacity
- a congenital anomaly/birth defect
- any other serious medical occurrence

Other important medical events may also be considered an SAE when, based on appropriate medical judgment, they jeopardize the participant or require intervention to prevent one of the outcomes listed.

An AE is considered to be life-threatening if, in the view of the Site Principal Investigator, the participant was at immediate risk of death from the reaction as it occurred. It does not include a reaction that, had it occurred in a more serious form, might have caused death.

Serious Adverse Events will be documented from the point of enrollment until the participant is exited from the study. Information recorded and reported shall include:

- A description of the event
- the date of event onset
- The relatedness of the event to the procedure
- The expectedness of the event
- The outcome of the event
- The date the event was first noticed by, or reported to the investigator

All ongoing Serious Adverse Events will be followed-up until the last study visit.

15.2.1 Serious Adverse Event Reporting

SAEs (as defined in Section 15.2) must be reported to the designated Medical Monitor immediately, and also to the Sponsor by email, and in no case later than within 24-hours of awareness of the event.

All SAEs that occur (whether or not related to study procedures) will be documented. The collection period for all SAEs will begin from the Sampling Visit and end after procedures for the final study visit have been completed.

In accordance with the standard operating procedures and policies of the local IRB/ERB, the Site Principal Investigator will report SAEs to the IRB/ERB.

15.3 Reporting incidents

An incident in a research study is:
• Something that should not have happened OR
• Something that should have happened but didn't

which, in either case, significantly affects any of the following:
• the rights and wellbeing of the study participant,
• the scientific value of the study,
• the compliance of the study with all applicable legal rules or ethics guidance including, as applicable, the Data Protection Act and the Human Tissue Act, or
• the reputation of the Sponsor.

This includes a requirement to report all serious breaches of protocol or GCP (if applicable).

All incidents must be reported through the appropriate host site incidents reporting system. For any host site where no United Kingdom National Health Service Trust is involved, the incident should be reported by completing the “Incident Report Form” that may be found at http://www.ucl.ac.uk/jro/postapproval.

15.4 Post-study Follow-up of Adverse Events

Any AE, including clinically significant physical examination findings, must be followed until the event resolves, the condition stabilizes, the event is otherwise explained, or the participant is lost to follow up. If resolved, a resolution date should be documented on the eCRF and in the source documents. The Site Principal Investigator is responsible for ensuring that follow up includes any supplemental investigations as may be indicated to elucidate the nature and/or causality of the AE. This may include additional laboratory tests or investigations, histopathological examinations, or consultation with other health care professionals as is medically indicated.

16. Statistical Methodology

16.1 Determination of Sample Size

The CSF and plasma samples collected in this study will be the basis for future biomarker analysis studies. Each of those studies will require a specific power calculation to determine how many samples to include in the analysis, but it is predicted, based on prior biomarker studies, that an n=50-75 per cohort will be sufficient for most studies. Since not all participants will be suitable for all biomarker studies, for example due to medication, we will aim to recruit 100 participants in each arm.

While most of the biomarker development focus is on earlier stages of the disease, it may also be important to assess some biomarkers at more advanced stages. Only sites with access to in-patient facilities will likely be able to recruit this cohort. Finally, for the biomarkers discovered and analyzed, it may be important to understand the stability of the biomarker within participants over relatively short time periods. Thus, approximately
20 participants per cohort will be invited to return for a repeat sampling visit 4-8 weeks after their first visit.

17. **Study Management**

17.1 **Roles and responsibilities**

Except where dictated by convention, statute or GCP, the roles and responsibilities of all parties involved in the study will be set forth in study site agreements or other contracts or subcontracts agreed by the parties concerned.

17.2 **Ethics and Regulatory Considerations**

This study will be conducted according to Good Clinical Practice (GCP), 21 CFR Part 50, (Protection of Human Subjects), 21 CFR Part 56 (Institutional Review Boards), International Conference on Harmonisation Guidance for Industry (ICH guidelines), E6 Good Clinical Practice: Consolidated Guidance, the Nuremberg Code, and the Declaration of Helsinki.

Sites will be responsible for obtaining all appropriate approvals from IRBs/ERBs, supported by a CHDI-approved informed consent form. ERB and/or IRB approval will be sought for each site in each country as per their regulations prior to the start of study activities at that site.

17.2.1 **Audits and Inspections**

CHDI, regulatory authority, Sponsor or IRB/ERB may visit the study site at any time during the study or after completion of the study to perform audits or inspections. The purpose of such an audit or regulatory inspection is to systematically and independently examine all study-related activities and documents to determine whether these activities were conducted according to the protocol, GCP, ICH guidelines, and any other applicable regulatory requirements. Site Principal Investigators should contact the Chief Investigator and CHDI immediately if contacted by a regulatory agency about an inspection at their site.

17.2.2 **Ethics Committee Approval**

This protocol and any amendments will be submitted to a properly constituted IRB/ERB, in accordance with the ICH guidelines, the applicable European Directives and local legal requirements, for approval of the study. Approval must be obtained in writing before the first participant can be recruited.

17.3 **Insurance**

University College London, the Sponsor, holds insurance against claims from participants for harm caused by their participation in this study. Participants may be able to claim compensation if they can prove that the Sponsor has been negligent. However, if this study is being carried out in a hospital, the hospital continues to have a duty of care to the participant of the study. The Sponsor does not accept liability for any breach in the hospital’s duty of care, or any negligence on the part of hospital employees. This applies whether the hospital is an NHS Trust or otherwise.

17.4 **Informed Consent Procedure**

All participants must give informed consent prior to undertaking study procedures and these informed consents must be obtained by clinical site staff using approved processes.
according to all applicable laws and regulations on GCP. At a minimum, the consent process will involve:

1. Provision of written, ERB and/or IRB-approved information about the study to potential participants;
2. Potential participants permitted sufficient opportunity to read the information and consider the options without maximum but with a recommended minimum of 24 hours;
3. Potential participants permitted sufficient opportunity to ask questions and receive satisfactory answers from the site study team;
4. Potential participants’ comprehension verified before signing a consent form; and
5. The voluntary signing of a consent form and countersigning by the study site personnel undertaking the consent process.

In the event that a site wishes to enroll participants with impaired capacity, specific ERB and/or IRB approval will be sought in advance before such participants are enrolled and a Legally Authorised Representative will sign on behalf of the participant.

Signed consent forms will be maintained in a secure designated location at the site.

17.5 Data Collection, Retention and Monitoring

17.5.1 Data Entry/Electronic Data Capture System

The data are entered electronically via secure internet-based technology. Access to the eCRFs is limited by password and can only be authorized by the global PI and issued by the study administrator. Each Site Principal Investigator in this study can only see data on participants from their own site. The data managers who are responsible for the data quality and integrity have access to all sites’ data. Clinical research monitors, who are responsible for monitoring data for site that are assigned, can only review the data from those sites. They are responsible for study monitoring and ensuring compliance with the study protocol.

17.5.2 Data Quality Control and Reporting

After data have been entered into the study database, a system of computerized data validation checks will be implemented and applied to the database on a regular basis. Query reports pertaining to data omissions and discrepancies will be forwarded to the Site Principal Investigator and Study Central Coordination for resolution. The study database will be updated in accordance with the resolved queries. All changes to the study database will be documented.

17.5.3 Archival of Data

The database is safeguarded against unauthorized access by established security procedures; appropriate backup copies of the database and related software files will be maintained. Databases are backed up by the database administrator in conjunction with any updates or changes to the database.

UCL and each participating site recognise that there is an obligation to archive study-related documents at the end of the study (as such end is defined within this protocol).
The Chief Investigator will archive the study master file at UCL for at least 20 years and in line with all applicable legal and statutory requirements. The principal investigator at each participating site agrees to archive his/her respective site’s study documents for at least 20 years and in line with all applicable legal and statutory requirements.

17.5.4 Study Master Files

Each site will maintain a Site Master File (SMF) containing all applicable regulatory, ethical and GCP documentation relating to the conduct of the study at the site. It will be the responsibility of each site's principal investigator to maintain this SMF.

17.5.5 Source Documents

The Site Principal Investigator should maintain source documents for each participant enrolled in the study. Source documents such as local laboratory ranges and reports, participant charts and doctors’ notes will be kept as part of the participants’ medical records. For participants who do not have a medical record per se, another method of documentation and record keeping will be employed, along with the obligation to retain source documents, such as laboratory reports, for the period of time specified in the site agreement. Participant files including medical records and signed participant informed consent forms must be available for review in the event the site is selected for monitoring, audits, or inspections.

17.5.6 Monitoring

The Sponsor is responsible for ensuring the proper conduct of the study with regard to ethics, protocol adherence, site procedures, integrity of the data, and applicable laws and/or regulations. At regular intervals during the study and following completion of the study, the Sponsor’s study monitors will contact the study site via visits to the site, telephone calls, and/or letters in order to review study progress, eCRF completion, and address any concerns or questions regarding the study conduct. During monitoring visits, the following aspects of study conduct will be carefully reviewed: informed consent of participants, participant recruitment, participant compliance with the study procedures, source data verification, use of concomitant therapy by participants, AE and SAE documentation and reporting, and quality of data. Records pertaining to these aspects are expected to be kept current.

The Site Principal Investigator must make study data accessible to the clinical monitor, to other authorized representatives of the Sponsor, and to regulatory inspectors.

17.5.7 Data transfer

In the study, data will be collected from patients in accordance with the patient consent form, patient information sheet (as applicable) and of this protocol.

The data will be appropriately sent to the data repository held and managed by service providers engaged by CHDI for storage and data monitoring, and UCL will act as the data controller of such data for the study.

The service providers engaged by CHDI will process, store and dispose of all study data in accordance with all applicable legal and regulatory requirements, including, as applicable, the Data Protection Act 1998 and any amendments thereto. All paper and digital records not uploaded to the study data repository will be retained at individual study sites in locked and/or password-protected form under the control of the Site Principal Investigators.
17.6 Biological samples (handling, processing and storage)

In the study, cerebrospinal fluid, plasma, serum and cells from CSF will be collected from patients in accordance with the patient consent form and patient information sheet (as applicable) and shall include all tissue samples or other biological materials and any derivatives, portions, progeny or improvements as well as all patient information and documentation supplied in relation to them. The biological samples will be appropriately sent to BioRep, Via Olgettina, 60, c/o DIBIT 2 - Palazzina San Michele 20132 Milan – Italy (or such other selected biorepository), for cataloguing and storage of the samples to be carried out in accordance with the protocol and the informed consents. BioRep (or such other selected biorepository) will process, store and dispose of all samples in accordance with all applicable legal and regulatory requirements, including, as applicable, the Human Tissue Act 2004 and any amendments thereto.

17.7 Amendments

Any amendments to the protocol will be written and approved by the Chief Investigator and CHDI. All amendments must be submitted to the Sponsor and IRB/ERB for approval prior to implementing the changes. In some instances, an amendment may require changes to the informed consent form, which also must be approved by CHDI and submitted for IRB/ERB approval prior to administration to study participants.

17.8 Record Keeping

17.8.1 Health Insurance Portability Accountability Act of 1996

The Site Principal Investigator agrees to comply with all applicable federal, state, and local laws and regulations relating to the privacy of patient health information, including, but not limited to, the Standards for Individually Identifiable Health Information, 45 CFR Parts 160 and 164 (the Health Insurance Portability Accountability Act of 1996 [HIPAA] Privacy Regulation). The Site Principal Investigator shall ensure that study participants authorize the use and disclosure of protected health information in accordance with HIPAA Privacy Regulation and in a form satisfactory to the Sponsor.

17.8.2 Retention of Study Documents

Study-related records must be retained for the period of time specified in the site agreement. The Site Principal Investigator must not destroy any study-related records without receiving approval from the Chief Investigator and CHDI. The Site Principal Investigator must notify the Chief Investigator in the event of accidental loss or destruction of any study records. If the Site Principal Investigator leaves the institution where the study was conducted, the Chief Investigator must be contacted to arrange alternative record storage options.

17.9 Reporting

After completion of the study, an abbreviated clinical study report will be prepared by the Chief Investigator.
18. Appendix A – Site Principal Investigator Obligations

The study protocol and the final version of the participant informed consent form will be approved by an IRB/ERB before enrollment of any participants. The opinion of the IRB/ERB will be dated and given in writing.

The Site Principal Investigator will ensure that the IRB/ERB will be promptly informed of all changes in the research activity and of all unanticipated problems including risk to participants. The Site Principal Investigator will not proceed with changes to the protocol until IRB/ERB approval has been obtained.

Written informed consent must be given freely and obtained from every participant prior to clinical study participation. The rights, safety, and well-being of the study participants are the most important considerations and should prevail over interests of science and society.

As described in GCP guidelines, site personnel involved in conducting this study will be qualified by education, training, and experience to perform their respective task(s). Site personnel will not include individuals who (a) are currently and have not ever been, debarred or convicted of a crime for which a person can be debarred or otherwise suspended or disqualified under any applicable laws, regulations or professional guidelines or (b) have ever been threatened to be debarred or indicted for a crime or otherwise engaged in any conduct or activity for which a person can be debarred or otherwise suspended or disqualified. Quality assurance systems and procedures will be implemented to assure the quality of every aspect of the study.

IRB/ERB Review/Approval/Reports

The protocol and informed consent for this study, including advertisements used to recruit participants, must be reviewed and approved by an appropriate IRB/ERB prior to enrollment of participants in the study. It is the responsibility of the Site Principal Investigator to assure that all aspects of the ethical review are conducted in accordance with the current Declaration of Helsinki, ICH, GCP, and/or local laws, whichever provide the greatest level of protection. A letter documenting the IRB/ERB approval which specifically identifies the study/protocol and a list of the committee members must be received by the Chief Investigator and CHDI prior to initiation of the study. Amendments to the protocol and informed consents will be subject to the same requirements as the original protocol and informed consents.

A progress report with a request for re-evaluation and re-approval will be submitted by the Site Principal Investigator to the IRB/ERB at intervals required by the IRB/ERC. A copy of the report will be sent to CHDI and the Sponsor as well as letters of re-evaluation and re-approval.

After completion or termination of the study, the Site Principal Investigator will submit a final report to the IRB/ERB and to CHDI, if required. This report should include: deviations from the protocol, the number and types of participants evaluated, and significant AEs, including deaths.

Study Documentation

The Site Principal Investigator is required to maintain complete and accurate study documentation in compliance with current GCP standards and all applicable federal, state, and local laws, rules, and regulations related to the conduct of a clinical study. Study
documentation includes CHDI/Site Principal Investigator correspondence, IRB/ERB correspondence, protocol and amendments, information regarding monitoring activities, participant exclusion records, eCRFs, and data queries.

Confidentiality

The anonymity of study participants will be protected by using an assigned participant number on eCRFs and other documents relating to the participant. Documents that identify the participant (e.g., the signed informed consent document) must be maintained in strict confidence by the Site Principal Investigator, except to the extent necessary to allow auditing by the Food and Drug Administration and other regulatory authorities or the clinical monitor and others as described in the informed consent.

Study Facilities

The Site Principal Investigator must ensure that there is a robust institutional policy on freezer failure that includes checks, alarms, emergency contact details, backup power supplies, CO2 cylinders and an infrastructure to transfer samples to an off-site facility if necessary.
19. References

